We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Surgical treatment of liver metastases from non-colorectal non-neuroendocrine carcinomas.
- Authors
Bauschke, Astrid; Altendorf-Hofmann, Annelore; Homman, Merten; Manger, Thomas; Pertschy, Jörg; Helfritzsch, Herry; Göbel, Hubert; Settmacher, Utz
- Abstract
Introduction: In the literature, results after surgical treatment of non-colorectal non-neuroendocrine liver metastases (NCNNLM) are reported that are often inferior to those from colorectal liver metastases. The selection of patients with favorable tumor biology is currently still a matter of discussion. Materials/methods: The retrospective data analysis was based on data that were collected for the multicenter study "Role of surgical treatment for non-colorectal liver metastases" in county Thuringia. Results: For the study, 637 patients were included from 1995 to 2018. 5 and 10-year survival of R0 resected patients were 33% and 19%, respectively. In the multi-variate analysis of the entire group, sex, timing, disease-free interval, number of metastases, R-classification as well as lymph node status of the primary lesion showed an independent statistical influence on the 5-year survival. In the group of R0 resected patients, disease-free interval, number of metastases and lymph node status of the primary lesion influenced the 5-year survival in the multi-variate analysis. In kidney malignancies, R-classification, timing and number of liver metastases were statistically significant in the multi-variate analysis of the 5-year survival, in mamma carcinomas only the R-classification. Conclusion: The Adam score identifies some risk factors which influence prognosis in most but not in all tumor entities. For kidney cancer and breast cancer it can be simplified.
- Subjects
THURINGIA (Germany); COLORECTAL liver metastasis; MULTIVARIATE analysis; PATIENT selection; RENAL cancer; CARCINOMA; HEPATOCELLULAR carcinoma
- Publication
Journal of Cancer Research & Clinical Oncology, 2022, Vol 148, Issue 2, p503
- ISSN
0171-5216
- Publication type
Article
- DOI
10.1007/s00432-021-03631-5